Not FDA-approved1,6Evidence: Animal and lab onlyNot a peptideHormones

IGF-1 LR31

Also called Long R3 IGF-I, Long-(Arg3) insulin-like growth factor-I1

Not a peptide: a protein, larger than a peptide, often looked up alongside peptides.

Key takeaway

IGF-1 LR3 is a lab-made version of the growth factor IGF-1 (insulin-like growth factor 1): 83 amino acids, which makes it a protein under FDA’s definition, not a peptide.1,2 It was made in the early 1990s as a research tool. Changing one amino acid and adding a short extension changed how it binds to IGF-binding proteins, and it acted more strongly than natural IGF-1 on several kinds of cells in the laboratory.3,4 No study in people and no FDA approval are reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.5,6,8

IGF-1 LR3 at a glance

Substance typeNot a peptide. FDA’s substance registry records IGF-1 LR3 as a protein of 83 amino acids, and FDA’s 2020 rule defines a protein as a chain of more than 40 amino acids.1,2
What it isHuman IGF-1 with arginine in place of glutamic acid at position 3 and a 13-amino-acid extension at the start, 83 amino acids in all, according to FDA’s substance registry.1
FDA statusNo FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,6
Human evidenceNone found. A 2010 report by doping-control researchers states that the effects of a tagged form of it in humans have not been described.5
Evidence strengthAnimal and lab studies only. The cited sources report no completed human study; the research base consists of animal, cell, or other laboratory work. How this label is assigned

What is IGF-1 LR3?

IGF-1 LR3, or long-(Arg3) insulin-like growth factor-I, is an engineered form of human IGF-1. FDA’s substance registry records it as a protein of 83 amino acids: IGF-1 with arginine at position 3, joined to a 13-amino-acid extension from pig growth hormone.1

FDA’s 2020 rule defines a protein as a chain of more than 40 amino acids, so at 83 amino acids IGF-1 LR3 counts as a protein, not a peptide.1,2

How is IGF-1 LR3 thought to work?

The 1992 study found that IGF-1 analogues with the added extension and the arginine-3 change were more potent than IGF-1 in cells that release IGF-binding proteins, and concluded that the gain came from changes in how they interact with those binding proteins.3

A 2025 study describes IGF-1 LR3 as an IGF-1 analogue with low affinity for IGF-binding proteins and high affinity for the IGF-1 receptor.4

What do human studies show?

None of the sources reviewed here describes a study of IGF-1 LR3 in people. A 2010 report by doping-control researchers, who identified a tagged form of it by mass spectrometry, states that its effects in humans have not been described.5

In growth-restricted fetal sheep, a week of IGF-1 LR3 did not improve growth, and it lowered amino acid levels in the blood, according to the 2025 study.4

What the evidence base contains

  • Animal or laboratory research Cell studies from 1992 in which IGF-1 analogues with an added extension, including the arginine-3 form, were more potent than natural IGF-1 at stimulating protein and DNA synthesis in rat muscle cells.3
  • Animal or laboratory research A 2025 study in growth-restricted fetal sheep, in which a week of IGF-1 LR3 did not improve growth.4

Evidence-strength label: Animal and lab studies only. How this label is assigned

Is IGF-1 LR3 FDA-approved?

None of the sources reviewed here reports an approval of IGF-1 LR3 by FDA.1,6

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list IGF-1 LR3.6

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. IGF-1 LR3 is not among them.7,8

Timeline

  1. Researchers describe IGF-1 analogues with an added extension, including the arginine-3 form, made as research tools.3
  2. Doping-control researchers report identifying a tagged form of IGF-1 LR3 and state that its effects in humans have not been described.5
  3. A study reports that IGF-1 LR3 did not improve growth in growth-restricted fetal sheep.4

What is still unknown?

Its effects and safety in people, which the sources reviewed here do not describe.5

How findings in cells and sheep relate to people: the 1992 study used laboratory cells, and the 2025 study treated fetal sheep for one week.3,4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for IGF-1 LR3: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for IGF-1 LR3 are a bounded selection, not every registration or paper about IGF-1 LR3. For the years before IGF-1 LR3 was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list IGF-1 LR3 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name IGF-1 LR3 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

No FDA approval reported; studied only in cells and animals. Evidence comes from cell and animal studies; doping-control researchers state that its effects in humans have not been described. IGF-1 LR3 is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of IGF-1 LR3?

No FDA approval reported; studied only in cells and animals. Evidence comes from cell and animal studies; doping-control researchers state that its effects in humans have not been described. IGF-1 LR3 is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
1
Source years
1
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to IGF-1 LR3?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

1Selected dated records
9Connected citations
1Populated source years2013
1/4Record lanes present

Registered human studies

Trial composition

0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

PubMed bibliography

Publication composition

1 of 1 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 1Research Support, Non-U.S. Gov't 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
1

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 1 dated record

Research hub

Explore the IGF-1 LR3 evidence record

Open all 1 records →
1Dated record
1Evidence type
1Cited public source
1Source year

Change ledger

Recently changed for IGF-1 LR3

Open all 1 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

Detection of His-tagged Long-R³-IGF-I in a black market product.

PubMed lists PMID 20675162 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-08-02 (day precision). PeptideScanner associated the retained record with the identity slug igf-1-lr3. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata

Official-source collections

Source records for IGF-1 LR3

Open the full research atlas →

Evidence types

Coverage by source year

Selected records span November 21, 2013 to November 21, 2013. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2,6
  • U.S. Department of Health and Human Services7
Dated updates connected to this profile · 1

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Detection of His-tagged Long-R³-IGF-I in a black market product.↗

    PubMed lists PMID 20675162 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-08-02 (day precision). PeptideScanner associated the retained record with the identity slug igf-1-lr3. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Long-(Arg3) insulin-like growth factor-I (IGF-1 LR3) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  2. 2
    Definition of the Term “Biological Product” (final rule, February 21, 2020) · FR Doc. 2020-03505 ↗

    Federal Register · Official source · Source checked November 16, 2026

  3. 3
    Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency (1992) · PMID 1378742 ↗

    Journal of Molecular Endocrinology · Official source · Source checked November 16, 2026

  4. 4
    IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep (2025) · PMID 39679943 ↗

    American Journal of Physiology. Endocrinology and Metabolism · Official source · Source checked November 16, 2026

  5. 5
    Detection of His-tagged Long-R3-IGF-I in a black market product (2010) · PMID 20675162 ↗

    Growth Hormone & IGF Research · Official source · Source checked November 16, 2026

  6. 6
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  7. 7
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  8. 8
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026